inclusion criteria: age ≥18 years laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay < 7 days prior to screening sars-cov-2 infection with duration at least 7 days (i e may be included on day 7) as determined by onset of symptoms (defined as day 1) 5 liters/minute of oxygen for at least 8 hours to maintain spo2 at ≥93%. a shorter duration is also accepted if presentation is acute, and the patient needs more than 10 liters/minute of oxygen, or high flow nasal cannula or non-invasive ventilation, to maintain spo2 at ≥93%.. crp > 70 mg/l with no non-sars-cov2 infections. values measured up to 48 hours before inclusion are accepted. ferritin > 500 µg/l values measured up to 48 hours before inclusion are accepted. at least two points on a scale of 0-3 where 1 point is awarded for each value of; lymphocytes < 1x 10(9)/l; d-dimer ≥ 0.5 mg/l and; lactate dehydrogenase ≥ 8 microkatal/l. the values do not have to be concurrently positive and may be up to 3 days old at inclusion. ability to provide informed consent signed by study patient willingness and ability to comply with study-related procedures/assessments in fertile females, willing to comply with effective contraceptive methods for up to 3 months after last dose of study drug. these may include surgical sterilization of patient or partner, intrauterine device or condoms. gestagen-only birth control pills (mini-pills), which do not increase the risk of deep venous thrombosis, may also be used. non-fertile woman is defined as more than 12 months of amenorrhea without an alternative medical cause or, in case of ambiguities, an fsh level in the postmenopausal range.

inclusion criteria: age ≥18 years laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay < 7 days prior to screening sars-cov-2 infection with duration at least 7 days (i e may be included on day 7) as determined by onset of symptoms (defined as day 1) 5 liters/minute of oxygen for at least 8 hours to maintain spo2 at ≥93%. a shorter duration is also accepted if presentation is acute, and the patient needs more than 10 liters/minute of oxygen, or high flow nasal cannula or non-invasive ventilation, to maintain spo2 at ≥93%.. crp > 70 mg/l with no non-sars-cov2 infections. values measured up to 48 hours before inclusion are accepted. ferritin > 500 µg/l values measured up to 48 hours before inclusion are accepted. at least two points on a scale of 0-3 where 1 point is awarded for each value of; lymphocytes < 1x 10(9)/l; d-dimer ≥ 0.5 mg/l and; lactate dehydrogenase ≥ 8 microkatal/l. the values do not have to be concurrently positive and may be up to 3 days old at inclusion. ability to provide informed consent signed by study patient willingness and ability to comply with study-related procedures/assessments in fertile females, willing to comply with effective contraceptive methods for up to 3 months after last dose of study drug. these may include surgical sterilization of patient or partner, intrauterine device or condoms. gestagen-only birth control pills (mini-pills), which do not increase the risk of deep venous thrombosis, may also be used. non-fertile woman is defined as more than 12 months of amenorrhea without an alternative medical cause or, in case of ambiguities, an fsh level in the postmenopausal range.

inclusion criteria: 1. age ≥18 years 2. laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay < 7 days prior to screening 3. sars-cov-2 infection with duration at least 7 days (i e may be included on day 7) as determined by onset of symptoms (defined as day 1) 4. 5 liters/minute of oxygen for at least 8 hours to maintain spo2 at ≥93%. a shorter duration is also accepted if presentation is acute, and the patient needs more than 10 liters/minute of oxygen, or high flow nasal cannula or non-invasive ventilation, to maintain spo2 at ≥93%.. 5. crp > 70 mg/l with no non-sars-cov2 infections. values measured up to 48 hours before inclusion are accepted. 6. ferritin > 500 µg/l values measured up to 48 hours before inclusion are accepted. 7. at least two points on a scale of 0-3 where 1 point is awarded for each value of; lymphocytes < 1x 10(9)/l; d-dimer ≥ 0.5 mg/l and; lactate dehydrogenase ≥ 8 microkatal/l. the values do not have to be concurrently positive and may be up to 3 days old at inclusion. 8. ability to provide informed consent signed by study patient 9. willingness and ability to comply with study-related procedures/assessments 10. in fertile females, willing to comply with effective contraceptive methods for up to 3 months after last dose of study drug. these may include surgical sterilization of patient or partner, intrauterine device or condoms. gestagen-only birth control pills (mini-pills), which do not increase the risk of deep venous thrombosis, may also be used. non-fertile woman is defined as more than 12 months of amenorrhea without an alternative medical cause or, in case of ambiguities, an fsh level in the postmenopausal range.

inclusion criteria: 1. age ≥18 years 2. laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay < 7 days prior to screening 3. sars-cov-2 infection with duration at least 7 days (i e may be included on day 7) as determined by onset of symptoms (defined as day 1) 4. 5 liters/minute of oxygen for at least 8 hours to maintain spo2 at ≥93%. a shorter duration is also accepted if presentation is acute, and the patient needs more than 10 liters/minute of oxygen, or high flow nasal cannula or non-invasive ventilation, to maintain spo2 at ≥93%.. 5. crp > 70 mg/l with no non-sars-cov2 infections. values measured up to 48 hours before inclusion are accepted. 6. ferritin > 500 µg/l values measured up to 48 hours before inclusion are accepted. 7. at least two points on a scale of 0-3 where 1 point is awarded for each value of; lymphocytes < 1x 10(9)/l; d-dimer ≥ 0.5 mg/l and; lactate dehydrogenase ≥ 8 microkatal/l. the values do not have to be concurrently positive and may be up to 3 days old at inclusion. 8. ability to provide informed consent signed by study patient 9. willingness and ability to comply with study-related procedures/assessments 10. in fertile females, willing to comply with effective contraceptive methods for up to 3 months after last dose of study drug. these may include surgical sterilization of patient or partner, intrauterine device or condoms. gestagen-only birth control pills (mini-pills), which do not increase the risk of deep venous thrombosis, may also be used. non-fertile woman is defined as more than 12 months of amenorrhea without an alternative medical cause or, in case of ambiguities, an fsh level in the postmenopausal range.

inclusion criteria: 1. laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay 2. sars-cov-2 infection with duration at least 7 days (as determined by onset of symptoms) 3. pao2 (or spo2)/fio2 < 26,8 kpa (200 mm hg) for at least 8 hours, corresponding to 5 liters/minute of oxygen to maintain spo2 at 94%. 4. crp > 70 mg/l with no non-sars-cov2 infections. 5. ferritin > 500 µg/l 6. at least two points on a scale of 0-3 where 1 point is awarded for each value of; lymphocytes < 1x 10(9)/l; d-dimer ≥ 0.5 mg/l and; lactate dehydrogenase ≥ 8 microkatal/l. 7. ability to provide informed consent signed by study patient 8. willingness and ability to comply with study-related procedures/assessments 9. in fertile females, willing to comply with effective contraceptive methods for up to 3 months after last dose of study drug. these may include birth control pills, surgical sterilization of patient or partner or intrauterine device. non-fertile woman is defined as more than 12 months of amenorrhea without an alternative medical cause or, in case of ambiguities, an fsh level in the postmenopausal range.

inclusion criteria: 1. laboratory-confirmed sars-cov-2 infection as determined by polymerase chain reaction (pcr) or other commercial or public health assay 2. sars-cov-2 infection with duration at least 7 days (as determined by onset of symptoms) 3. pao2 (or spo2)/fio2 < 26,8 kpa (200 mm hg) for at least 8 hours, corresponding to 5 liters/minute of oxygen to maintain spo2 at 94%. 4. crp > 70 mg/l with no non-sars-cov2 infections. 5. ferritin > 500 µg/l 6. at least two points on a scale of 0-3 where 1 point is awarded for each value of; lymphocytes < 1x 10(9)/l; d-dimer ≥ 0.5 mg/l and; lactate dehydrogenase ≥ 8 microkatal/l. 7. ability to provide informed consent signed by study patient 8. willingness and ability to comply with study-related procedures/assessments 9. in fertile females, willing to comply with effective contraceptive methods for up to 3 months after last dose of study drug. these may include birth control pills, surgical sterilization of patient or partner or intrauterine device. non-fertile woman is defined as more than 12 months of amenorrhea without an alternative medical cause or, in case of ambiguities, an fsh level in the postmenopausal range.